Skip to main content
Premium Trial:

Request an Annual Quote

Millennium Identifies Possible Biomarker for Response to Atherosclerosis Candidate

NEW YORK (GenomeWeb News) - Millenium Pharmaceuticals said Tuesday it has identified a genomic biomarker during Phase II trials of a cardiovascular disease drug.
The company said it has found that 11.3 percent of patients treated with its MLN1202 monoclonal antibody had a reduction of C-reactive protein (CRP), and that CRP reductions were more likely in patients with a SNP that was identified in 53 percent of the study population.
The company also said MLN1202 lowered CRP levels similarly in subjects on lipid-lowering agents, such as statins, compared to those not on these agents, and that MLN1202 was well-tolerated with no evidence of systemic suppressed immunity.
"The association of a genomic biomarker with the biologic activity of the investigational drug validates our approach of using biomarkers to tailor drug treatments,” Millenium CSO Nancy Simonian said in a statement.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.